Abstract:Kevin Zambrano, 1– 5 Karina Castillo, 1, 2 Sebastian Peñaherrera, 1, 2, 4 Henry C Vasconez, 1, 2 Andrés Caicedo, 1– 4 Antonio WD Gavilanes 1, 3 1 Department of Health Sciences, Universidad San Francisco de Quito USFQ, School of Medicine, Quito, Ecuador; 2 Institute of Biomedical Research (Ibiomed), Universidad San Francisco de Quito USFQ, Quito, Ecuador; 3 School for Mental Health and Neuroscience (Mhens), Maastricht University, Maastricht, the Netherlands; 4 Mito-Act Research Consortium, Quito, Ecuador; 5 Neuroscience Institute, Universidad San Francisco de Quito USFQ, Quito, Ecuador Correspondence: Andrés Caicedo; Antonio WD Gavilanes, Email ; COVID-19, a highly infectious disease, caused a worldwide pandemic in early 2020. According to the World Health Organization (WHO), COVID-19 has resulted in approximately 774 million cases and around 7 million deaths. The effects of COVID-19 are well known; however, there is a lack of information on the pathophysiological mechanisms underlying the symptoms that comprise Post-Acute COVID-19 Syndrome (PACS) or Long COVID-19. Neurological sequelae are common, with cognitive dysfunction being one of the foremost symptoms. Research indicates that elevated inflammatory levels and increased oxidative stress may play a role in the etiology and severity of PACS. Treatment options are extremely limited, and there is no consensus among the medical and scientific communities on how to manage the disease. Nevertheless, many scientists advocate for using antioxidants for symptomatic therapy and cognitive behavior therapy for supportive care. Additionally, current research aims to ameliorate several aspects of the inflammatory cascade. This review highlights the intracellular and extracellular pathways crucial to the neurological manifestations of PACS, providing valuable information for healthcare professionals and scientists. Given the complex nature of PACS, understanding these pathways is essential for developing new treatment options. Assessing PACS is challenging, and reviewing current therapeutic options while proposing a triad of potential therapeutic elements will add value to clinical assays and guidelines. Current therapeutic strategies, such as antioxidants/vitamin supplements, neurogenic stem cell therapy, and mitochondrial therapy, could be combined to enhance their effectiveness. Future research should focus on validating these approaches and exploring new avenues for the effective treatment of PACS. Keywords: post-acute COVID-19 syndrome, PACS, long COVID-19, cognitive dysfunction, mitochondrial therapy Graphical SARS-CoV-2 is a highly transmissible virus that causes the acute multisystem illness known as Coronavirus Disease 2019 (COVID-2019). 1,2 The widespread infection and high mortality rate led the World Health Organization (WHO) to declare COVID-19 a pandemic on March 11, 2020. 3 By the start of 2022, it had already spread to 237 countries and territories around the world. 3 It has been estimated as of early 2024, that COVID-19 is responsible for 774 million cases and around 7 million deaths. 4 To put this into perspective, the leading cause of death in 2019 was ischemic heart disease with around 8.9 million deaths. 5 This comparison is astonishing because mortality due to infectious disease has not been a lead cause of death for decades. Moreover, this highlights the importance of establishing early alarm signs of a pandemic danger, how to prevent fast dissemination, research consortiums to understand the pathophysiology of the disease, better understand sequelae, and develop interdisciplinary approaches. During COVID-19 infection, patients can present a variety of symptoms with the most common being fever, cough, fatigue, dyspnea, increased sputum, joint pain, diarrhea, altered smell, and altered taste. 6,7 Most patients' symptoms will resolve themselves in a couple of weeks. Nevertheless, some individuals may develop new symptoms such as fatigue, headache, and anosmia, among others, weeks after a presumed recovery. Approximately 10% of COVID-19 patients experience persistent or recurring symptoms that extend beyond 4–12 weeks post-infection. 1,8 The United Kingdom National Institute for Health and Care Excellence has established that ongoing symptomatic COVID-19 can occur from 4–12 weeks after infection while Post-Acute COVID-19 syndrome (PACS) or Long COVID-19 persists for more than 12 weeks. 1 This ongoing burden of persistent symptoms highlights the critical need for continued research and effective management strategies for PACS to improve patient outcomes and quality of life. PACS has bee -Abstract Truncated-

The Aftermath of COVID-19: Exploring the Long-Term Effects on Organ Systems

Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms

Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC)

Post-Acute Sequelae of Covid-19: A System-wise Approach on the Effects of Long-Covid-19

Persisting Shadows: Unraveling the Impact of Long COVID-19 on Respiratory, Cardiovascular, and Nervous Systems

Beyond acute infection: mechanisms underlying post‐acute sequelae of COVID‐19 (PASC)

Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations

Beyond the acute illness: Exploring long COVID and its impact on multiple organ systems

Understanding Post-COVID-19: Mechanisms, Neurological Complications, Current Treatments, and Emerging Therapies

A Disease Hidden in Plain Sight: Pathways and Mechanisms of Neurological Complications of Post-acute Sequelae of COVID-19 (NC-PASC)

Research progress of post-acute sequelae after SARS-CoV-2 infection

Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms

Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19

Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach

Postacute Sequelae of SARS-CoV-2 in Children

Three-Month Follow-Up of the Post-COVID Syndrome after Admission to a Specialised Post-COVID Centre—A Prospective Study Focusing on Mental Health with Patient Reported Outcome Measures (PROMs)

Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals

PASC (Post Acute Sequelae of COVID-19) is associated with decreased neutralizing antibody titers in both biological sexes and increased ANG-2 and GM-CSF in females

A Systematic Evaluation of Risk Predictors for COVID-19 Sequelae

Multiple early factors anticipate post-acute COVID-19 sequelae

Long COVID or Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and the Urgent Need to Identify Diagnostic Biomarkers and Risk Factors